In phase 3 clinical trial, upadacitnib proved superior to placebo and adalimumab in improving the signs and symptoms of RA in patients on stable background methotrexate.
Courses before the 2021 State-of-the-Art Clinical Symposium will focus heavily on what’s new in practice, including mastering evaluation and management changes and access to treatments in rheumatology. Early bird registration ends March 31.
The ACR has joined with a coalition of organizations dedicated to improving the health and wellbeing of children and adolescents to request $50 million to fund the Pediatric Subspecialty Loan Repayment Program.
Introduced in the Senate on Feb. 25, the bill would amend the Employee Retirement Income Security Act to provide a clear process and circumstances for requesting medical exceptions to step therapy protocols.
Research from Ellingwood et al. examines how often patients diagnosed with early RA experience episodic joint inflammation and describes characteristics that may result in RA development.
The editors of The Rheumatologist would like to thank all of the rheumatologists, rheumatology professionals and professional writers who took the time and effort in an unprecedented pandemic year to ensure we could continue to bring you the important clinical guidelines, case reports, current research, COVID-19 coverage and so much more. This publication would not…
Now in its 16th year, the Wisconsin Rheumatology Association engages and supports rheumatology professionals through advocacy sessions, annual meetings and continuing medical education-accredited events.
(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests. Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target…